Chilton Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$258K Sell
10,735
-6,000
-36% -$157K 0.01% 207
2026
Q1
$470K Buy
16,735
+277
+2% +$7.38K 0.02% 175
2025
Q4
$410K Sell
16,458
-63,537
-79% -$1.6M 0.01% 177
2025
Q3
$2.04M Buy
79,995
+15,738
+24% +$388K 0.07% 104
2025
Q2
$1.56M Sell
64,257
-1,138
-2% -$26.5K 0.06% 109
2025
Q1
$1.66M Sell
65,395
-1,197
-2% -$31.3K 0.07% 103
2024
Q4
$1.77M Sell
66,592
-3,134
-4% -$85K 0.07% 103
2024
Q3
$2.02M Buy
69,726
+804
+1% +$23.5K 0.08% 100
2024
Q2
$1.93M Sell
68,922
-934
-1% -$25.7K 0.09% 100
2024
Q1
$1.94M Sell
69,856
-6,888
-9% -$191K 0.09% 100
2023
Q4
$2.21M Sell
76,744
-21,250
-22% -$642K 0.11% 100
2023
Q3
$3.25M Sell
97,994
-1,373
-1% -$48.6K 0.18% 85
2023
Q2
$3.64M Buy
99,367
+522
+0.5% +$20.3K 0.2% 80
2023
Q1
$4.03M Buy
98,845
+2,148
+2% +$92.8K 0.23% 80
2022
Q4
$4.95M Sell
96,697
-1,495
-2% -$71.7K 0.31% 77
2022
Q3
$4.3M Buy
98,192
+4,676
+5% +$227K 0.29% 78
2022
Q2
$4.9M Buy
93,516
+5,652
+6% +$288K 0.3% 76
2022
Q1
$4.55M Buy
87,864
+46
+0.1% +$2.39K 0.24% 80
2021
Q4
$5.19M Sell
87,818
-353
-0.4% -$17.5K 0.26% 79
2021
Q3
$3.79M Buy
88,171
+8,762
+11% +$388K 0.21% 87
2021
Q2
$3.11M Buy
79,409
+65,777
+483% +$2.56M 0.18% 90
2021
Q1
$494K Buy
13,632
+3,636
+36% +$129K 0.03% 146
2020
Q4
$368K Sell
9,996
-793
-7% -$29.1K 0.03% 152
2020
Q3
$376K Sell
10,789
-303
-3% -$10.6K 0.03% 151
2020
Q2
$344K Sell
11,092
-4,420
-28% -$150K 0.03% 152
2020
Q1
$480K Sell
15,512
-527
-3% -$18K 0.05% 135
2019
Q4
$596K Hold
16,039
0.05% 150
2019
Q3
$547K Sell
16,039
-184
-1% -$6.69K 0.05% 151
2019
Q2
$667K Sell
16,223
-1,322
-8% -$52.5K 0.06% 138
2019
Q1
$707K Buy
17,545
+539
+3% +$21.6K 0.06% 136
2018
Q4
$704K Sell
17,006
-5,270
-24% -$219K 0.07% 140
2018
Q3
$931K Sell
22,276
-1,611
-7% -$62K 0.08% 140
2018
Q2
$822K Sell
23,887
-3,149
-12% -$108K 0.07% 145
2018
Q1
$910K Sell
27,036
-32,776
-55% -$1.13M 0.08% 137
2017
Q4
$2.06M Sell
59,812
-13,966
-19% -$476K 0.19% 86
2017
Q3
$2.5M Sell
73,778
-15,241
-17% -$490K 0.24% 84
2017
Q2
$2.84M Sell
89,019
-198,374
-69% -$6.26M 0.31% 77
2017
Q1
$9.33M Buy
287,393
+2,994
+1% +$94.4K 0.93% 47
2016
Q4
$8.76M Buy
284,399
+1,147
+0.4% +$35K 0.92% 50
2016
Q3
$9.1M Buy
283,252
+6,246
+2% +$209K 0.92% 50
2016
Q2
$9.25M Buy
277,006
+46,359
+20% +$1.48M 0.9% 51
2016
Q1
$6.49M Buy
230,647
+24,134
+12% +$689K 0.65% 65
2015
Q4
$6.33M Buy
206,513
+90,183
+78% +$2.84M 0.66% 65
2015
Q3
$3.47M Buy
116,330
+85,256
+274% +$2.73M 0.36% 85
2015
Q2
$989K Sell
31,074
-54
-0.2% -$1.76K 0.09% 114
2015
Q1
$1.03M Buy
31,128
+360
+1% +$11.4K 0.1% 114
2014
Q4
$909K Buy
30,768
+1,264
+4% +$36.2K 0.09% 122
2014
Q3
$828K Buy
29,504
+3,053
+12% +$85.7K 0.09% 124
2014
Q2
$745K Sell
26,451
-1,364
-5% -$38.9K 0.07% 129
2014
Q1
$848K Hold
27,815
0.09% 121
2013
Q4
$808K Sell
27,815
-1,038
-4% -$30.2K 0.09% 128
2013
Q3
$786K Sell
28,853
-1,107
-4% -$30.1K 0.09% 129
2013
Q2
$796K Buy
+29,960
New +$828K 0.1% 129

Other funds holding PFE

Chilton Capital Management's PFE Position: Q2 2026 in Review

Chilton Capital Management reduced its Pfizer (PFE) stake by 36% in Q2 2026, selling an estimated $157K and leaving 10,735 shares worth $258K. The position accounts for 0.01% of the portfolio, ranked #207.

Chilton Capital Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $9.33M in Q1 2017. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Chilton Capital Management held 10,735 shares of Pfizer worth $258K as of Q2 2026.
  • Chilton Capital Management sold 6,000 Pfizer shares in Q2 2026, an estimated $157K.
  • Pfizer made up 0.01% of Chilton Capital Management's portfolio in Q2 2026, its #207 holding.
  • Chilton Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Chilton Capital Management's Pfizer position peaked at $9.33M in Q1 2017.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Chilton Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.